Loading...

Stay current with insights from our analysts and industry updates.  Subscribe to one of our HealthCheck24 newsletters to receive regular weekly insights by email. We also offer customised newsletters to keep your management, sales and marketing teams fully informed - contact us to find out more.

Zimmer Biomet achieving synergies and rapid sales in Asia-Pacific

Image

03-Nov-15 In the first quarter after its merger, Zimmer Biomet has reported it expects to complete commercial integration by the end of 2015. It also reported progress on its sales channel integration, evidenced by sequential sales improvement in its Asia-Pacific and Europe, Middle East & Africa (EMEA) regions, where Knee orthopaedics sales increased 9% and 6% respectively. [image: Zimmer Biomet]

Read More

Validic grows internationally, enhances mHealth offering

Image

05-Nov-15 US-based digital health platform provider Validic has announced a slew of achievements over the last year, including new customers, 68% more integrated devices and applications, and international expansion. The company says it is now "reaching more than 160 million lives in 47 countries" and has built a presence in 11 countries, spanning Asia, Latin America, Europe and the Middle East. [image: Validic]

Read More

India’s first dedicated Medical Device Park

Image

09-Nov-15 Chief Minister of Andhra Pradesh, Chandrababu Naidu has taken in-principle decision to develop a dedicated 200 acre industrial park for the manufacture of medical devices in his state. The 200 acre exclusive park will spur domestic production of medical devices, and help reduce import dependency in this sector while creating employment and economic growth. [image: ET Healthworld]

Read More

Hanmi Pharmaceutical signs Sanofi diabetes mega deal

Image

06-Nov-15 Korea's Hanmi Pharmaceutical has signed a contract with Sanofi to export USD4 bn worth of diabetes treatment technology, in a deal worth almost 30% of the value of the entire Korean pharma industry. Sanofi gains an exclusive worldwide license to develop and commercialize drugs based on the materials, except in Korea and China, where Hanmi retains co-commercialization rights. [image: Business Korea]

Read More
Share